Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GeneDx Holdings (WGS) Change in Accured Expenses (2020 - 2025)

GeneDx Holdings (WGS) has disclosed Change in Accured Expenses for 6 consecutive years, with $6.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses rose 154.38% to $6.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $12.1 million, a 158.96% increase, with the full-year FY2025 number at $12.1 million, up 158.96% from a year prior.
  • Change in Accured Expenses was $6.9 million for Q4 2025 at GeneDx Holdings, up from -$2.0 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $31.8 million in Q2 2022 to a low of -$14.5 million in Q3 2023.
  • A 5-year average of $139200.0 and a median of -$2.8 million in 2025 define the central range for Change in Accured Expenses.
  • Peak YoY movement for Change in Accured Expenses: surged 65806.86% in 2021, then plummeted 440.79% in 2023.
  • GeneDx Holdings' Change in Accured Expenses stood at $21.0 million in 2021, then plummeted by 71.88% to $5.9 million in 2022, then plummeted by 256.79% to -$9.3 million in 2023, then tumbled by 37.42% to -$12.7 million in 2024, then surged by 154.38% to $6.9 million in 2025.
  • Per Business Quant, the three most recent readings for WGS's Change in Accured Expenses are $6.9 million (Q4 2025), -$2.0 million (Q3 2025), and -$3.6 million (Q2 2025).